Protego Ventures has closed its debut $125 million fund, positioning itself as Israel's first dedicated defense technology venture capital firm. The fully-subscribed round marks a significant shift in how institutional capital approaches emerging technology investment—moving away from geography-agnostic generalist funds toward sector-and-nation-specific thesis investing. The timing is notable given escalating geopolitical tensions and renewed government focus on defense innovation across developed economies. Protego's emergence suggests that limited partners now view defense tech not as a niche adjacent to enterprise software, but as a distinct asset class worthy of specialized expertise and dedicated capital pools.
The fund's $125 million close arrives amid broader evidence that venture capital is fragmenting by thesis rather than consolidating around mega-funds. This week alone saw $400 million rounds for cybersecurity unicorns and substantial funding for drug discovery, neurotech, and specialized AI agents—including $6.7 million for Dextr AI's hotel automation platform and $33 million for Tiny Health's microbiome testing business. Each represents capital flowing into vertical-specific solutions rather than generalist large language model plays. Protego's specialization mirrors this pattern: instead of backing AI companies broadly, the fund commits to the narrower, higher-conviction thesis that Israeli founders have distinct advantages in defense innovation.
The emergence of nation-specific defense funds also reflects a broader recalibration of venture strategy around geopolitical supply chains and regulatory alignment. Israeli venture capital has historically focused on enterprise software and semiconductors; Protego's debut signals that institutional LPs now view defense technology as equally important and appropriately localized. This contrasts sharply with the era of purely neutral, technology-agnostic venture strategies. While tech layoffs continue—reaching 94,046 through August—capital continues flowing to specialized startups, suggesting founders with focused theses are outcompeting those pitching broad platforms. Protego's close demonstrates that venture's fragmentation into specialized verticals may be reshaping how founders raise and how capital deploys, independent of macro hiring cycles.